BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 23420490)

  • 21. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
    Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
    J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
    Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo.
    Farrugia AN; Atkins GJ; To LB; Pan B; Horvath N; Kostakis P; Findlay DM; Bardy P; Zannettino AC
    Cancer Res; 2003 Sep; 63(17):5438-45. PubMed ID: 14500379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
    Bolzoni M; Storti P; Bonomini S; Todoerti K; Guasco D; Toscani D; Agnelli L; Neri A; Rizzoli V; Giuliani N
    Exp Hematol; 2013 Apr; 41(4):387-97.e1. PubMed ID: 23178378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
    Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
    Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
    Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
    J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toll-Like Receptor 2 Stimulation of Osteoblasts Mediates Staphylococcus Aureus Induced Bone Resorption and Osteoclastogenesis through Enhanced RANKL.
    Kassem A; Lindholm C; Lerner UH
    PLoS One; 2016; 11(6):e0156708. PubMed ID: 27311019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on the pathogenesis of osteolysis in multiple myeloma patients.
    Giuliani N; Colla S; Rizzoli V
    Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
    Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
    Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Upregulation of brain-derived neurotrophic factor in advanced gastric cancer contributes to bone metastatic osteolysis by inducing long pentraxin 3.
    Choi B; Lee EJ; Shin MK; Park YS; Ryu MH; Kim SM; Kim EY; Lee HK; Chang EJ
    Oncotarget; 2016 Aug; 7(34):55506-55517. PubMed ID: 27458153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of new targets for therapy of osteolytic bone disease in multiple myeloma.
    Hjertner Ø; Standal T; Børset M; Sundan A; Waage A
    Curr Drug Targets; 2005 Sep; 6(6):701-11. PubMed ID: 16178802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
    Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
    Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
    Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
    Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
    Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
    J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts.
    Tada T; Jimi E; Okamoto M; Ozeki S; Okabe K
    Int J Cancer; 2005 Aug; 116(2):253-62. PubMed ID: 15800904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RANK ligand as a therapeutic target for bone metastases and multiple myeloma.
    Roodman GD; Dougall WC
    Cancer Treat Rev; 2008 Feb; 34(1):92-101. PubMed ID: 17964729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Expression and significance of brain-derived neurotrophic factors and receptors in multiple myeloma].
    Sun CY; Hu Y; Wu T; Wang YD; He WJ
    Zhonghua Nei Ke Za Zhi; 2005 Dec; 44(12):906-9. PubMed ID: 16409727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
    Clézardin P
    Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zebrafish scales respond differently to in vitro dynamic and static acceleration: analysis of interaction between osteoblasts and osteoclasts.
    Kitamura K; Takahira K; Inari M; Satoh Y; Hayakawa K; Tabuchi Y; Ogai K; Nishiuchi T; Kondo T; Mikuni-Takagaki Y; Chen W; Hattori A; Suzuki N
    Comp Biochem Physiol A Mol Integr Physiol; 2013 Sep; 166(1):74-80. PubMed ID: 23632157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation.
    Tat SK; Padrines M; Theoleyre S; Couillaud-Battaglia S; Heymann D; Redini F; Fortun Y
    Bone; 2006 Oct; 39(4):706-15. PubMed ID: 16750945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.